{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-22-000079","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2022-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.772560+00:00","generated_at":"2026-06-23T09:47:50.701738+00:00","sec_items":["5.03","5.07","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Caladrius stockholders approve merger with Cend Therapeutics, 1:15 reverse split, name change to Lisata Therapeutics","bullets":["Merger with Cend approved: 25,973,235 for, 2,912,622 against, 172,676 abstain.","Reverse stock split at 1:15 ratio approved: 31,343,168 for, 7,665,240 against.","Name change to Lisata Therapeutics approved: 34,861,858 for, 4,003,401 against.","Merger close expected Sep 15, 2022; combined company to trade as LSTA on Nasdaq.","Board set reverse split ratio at 1:15; effective Sep 14, 2022 at 5:00 PM ET."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-22-000079","json":"https://secwatch.observer/filing/0000320017-22-000079.json","markdown":"https://secwatch.observer/filing/0000320017-22-000079.md","text":"https://secwatch.observer/filing/0000320017-22-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000079/0000320017-22-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001722000079/clbs-20220913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:47:50.701738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}